U.S. Patient and Trademark Office, U.S. DEPARTMENT OF COMM.
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid CMB control nu

		Filing Date		200	
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor Gard		a-Ro	
	(Not for submission under 37 CFR 1.99)	Art Unit		164	
1.	(Not for Submission under or of it iso)	Examiner Name Wa		re, Det	

Application Number		10562842		
Filing Date		2005-12-29		
First Named Inventor Gard		cia-Rodenas et al.		
Art Unit		1645		
Examiner Name	Ware	, Deborah		
Attorney Docket Numb	er	112701-696		

				U.	S.PATENTS			Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date		of cited Decument		Pages,Columns,Lines where Relevant Passages or Releva Figures Appear	
	1	6207638		2001-03-27	Portman				
	2								
If you wisi	h to a	i dd additional U.S. Pate	nt citatio	n information	please click the	Add button.	_	Add	
			U.S.P	ATENT APP	LICATION PUB	LICATIONS		Remove	
		Name of Par of cited Doc	tentee or Applicant ument	Releva		ines where es or Relevar			
	1	20030004095		2003-01-02	Reimer et al.				
	2	20030000216		2001-09-13	Portman				
	3	20030072822		2003-04-17	Ribnicky et al	ı			
If you wis	h to a	dd additional U.S. Publ	ished Ap		tion information		d button	Add	
		I		FUREIGN P	AIENI DOCUM	T	T a	$\overline{}$	umns,Lines
Examiner Initial*	Cite No	Foreign Document Number ³	Countr Code ²		d Publication le4 Date	Name of Patente Applicant of cited Document	e or	vhere Rele	vant or Relevant

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

2002-020295

Application Number		10562842		
Filing Date		2005-12-29		
First Named Inventor Gard		a-Rodenas et al		
Art Unit		1645		
Examiner Name Ware		Deborah		
Attorney Docket Number		112701-696		

	2	WO 02/11564	wo		2002-02-14				
If you wisi	h to a	dd additional Forei	gn Patent Document	citation	information pl	ease click the Add buttor	Add		
			NON-PATE	NT LITE	ERATURE DO	CUMENTS	Remove		
Examiner Initials*	Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item Initials* No look, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.					Тs			
	Belcoração et al., "The effects of dietary protein on sit growth, body composition and insulin sensitivity," Asia Pacific Journal of Climcal Nutrition, vol. 12 Suppl. p. S42, XP009042775 ISSN: 0964-7058								
2 Borrie et al., "Slow and fast dielary proteins differently modulate postprandial protein accretion," Proc. Natl. Acad. Sci. USA, Vol. 94, pp. 14930-14935, December 1997									
If you wis	If you wish to add additional non-patent literature document citation information please click the Add button Add								
			Đ	AMINE	R SIGNATUR	E			
Examiner	Signa	ature				Date Considered			
*EXAMIN	*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a								

2002-01-23

1 See Kinz Code of USPTO Patent Documents at twee USPTO_GOUY or MPEP 80104. Enter of tions that issued the document, by the two-letter of the Southern See Code (WIPO Southern See Code Southern

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10562842
Filing Date		2005-12-29
First Named Inventor Gard		a-Rodenas et al
Art Unit		1645
Examiner Name Ware		, Deborah
Attorney Docket Number		112701-696

CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.98 to	make the	appropriate selection(s	s):
---------------	----------	-------------	----------	-------------------------	-----

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e/11).

ΩR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(s)(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/Robert M. Barrett/	Date (YYYY-MM-DD)	2006-09-27
Name/Print	Robert M. Barrett	Registration Number	30142

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is foll field and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenan's Afford, U.S. Department of Commence, P. 0. Bot 1450, Alexandria, V.32.511.450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. 0. Box 1450, Alexandria, V.32.311.450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to the patient application or patient. If you do not furnish the requested the process another examines your submission, which may visually intermediate or for extension or about those when the basic high process another examines your submission, which may visually intermediate or for extension or a submission of the basic high process another examines your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pusuant to 5 U.S.C. 552a(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs a part of that apency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record via set float in an application which became abandomed or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issuand patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.